Seyed Mehrab Safdari: Factor VII Padua and the Limits of FVII Activity
Seyed Mehrab Safdari, Molecular Laboratory Technician at Tehran University of Medical Sciences, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Annals of Hematology, adding:
“In my previous post, I shared findings from our cohort on Factor VII Padua, particularly the marked differences in FVII activity depending on the thromboplastin reagent used.
To put those findings into a wider context, we reviewed the published literature on Factor VII Padua. Our systematic review included 75 patients from 36 publications.
The clinical picture was highly variable. Nearly half of patients with available bleeding data were asymptomatic, and very low FVII activity, especially with rabbit brain thromboplastin, did not reliably reflect bleeding severity.
Thrombotic events, including DVT and PE, were also reported, particularly in homozygous and compound heterozygous patients.
The mechanism behind this paradox is still unclear, and understanding why thrombosis occurs in Factor VII Padua could be an important next step for future research.
What I take from these findings is that FVII activity should not be interpreted on its own.
The thromboplastin reagent, the patient’s bleeding history, previous hemostatic challenges, and genotype, when available, all need to be considered together.
This review supports the same message we saw in our previous study: A very low FVII activity does not always tell the whole story.”
Title: Factor VII Padua: a systematic review of reported cases, diagnosis, clinical manifestations, and management strategies
Authors: Seyed Mehrab Safdari, Mahmood Shams, Samin Alavi, Akbar Dorgalaleh

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 04:31Aakriti Gupta: Anticoagulation for Leaflet Thickening After TAVR
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis
-
Nov 14, 2026, 23:46Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning
-
Nov 14, 2026, 23:33Mona Alfaraj: International Pathology Day Promotes Education in Hemoglobinopathy Diagnostics